AU2019354714B9 - Humanised anti-N-truncated amyloid beta monoclonal antibody - Google Patents

Humanised anti-N-truncated amyloid beta monoclonal antibody

Info

Publication number
AU2019354714B9
AU2019354714B9 AU2019354714A AU2019354714A AU2019354714B9 AU 2019354714 B9 AU2019354714 B9 AU 2019354714B9 AU 2019354714 A AU2019354714 A AU 2019354714A AU 2019354714 A AU2019354714 A AU 2019354714A AU 2019354714 B9 AU2019354714 B9 AU 2019354714B9
Authority
AU
Australia
Prior art keywords
nt4x
seq
antibody
binding
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019354714A
Other languages
English (en)
Other versions
AU2019354714B2 (en
AU2019354714A1 (en
Inventor
Preeti BAKRANIA
Thomas Bayer
Alex Brown
Mark Carr
Sarah Davies
Gareth HALL
David Matthews
Chido MPAMHANGA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaetsmedizin Goettingen Georg August Universitaet
LifeArc
Original Assignee
Georg August Universitaet Goettingen Stiftung Oeffentlichen Rechts Universitaetsmedizin
Universitaetsmedizin Goettingen Georg August Universitaet
LifeArc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georg August Universitaet Goettingen Stiftung Oeffentlichen Rechts Universitaetsmedizin, Universitaetsmedizin Goettingen Georg August Universitaet, LifeArc filed Critical Georg August Universitaet Goettingen Stiftung Oeffentlichen Rechts Universitaetsmedizin
Publication of AU2019354714A1 publication Critical patent/AU2019354714A1/en
Publication of AU2019354714B2 publication Critical patent/AU2019354714B2/en
Application granted granted Critical
Publication of AU2019354714B9 publication Critical patent/AU2019354714B9/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2019354714A 2018-10-04 2019-10-02 Humanised anti-N-truncated amyloid beta monoclonal antibody Active AU2019354714B9 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201816210 2018-10-04
GB1816210.7 2018-10-04
PCT/EP2019/076772 WO2020070225A1 (en) 2018-10-04 2019-10-02 Humanised anti-n-truncated amyloid beta monoclonal antibody

Publications (3)

Publication Number Publication Date
AU2019354714A1 AU2019354714A1 (en) 2021-04-29
AU2019354714B2 AU2019354714B2 (en) 2026-05-21
AU2019354714B9 true AU2019354714B9 (en) 2026-07-02

Family

ID=68136417

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019354714A Active AU2019354714B9 (en) 2018-10-04 2019-10-02 Humanised anti-N-truncated amyloid beta monoclonal antibody

Country Status (12)

Country Link
US (1) US12297261B2 (enExample)
EP (1) EP3861023A1 (enExample)
JP (1) JP7610515B2 (enExample)
KR (1) KR102862077B1 (enExample)
CN (1) CN113056480B (enExample)
AU (1) AU2019354714B9 (enExample)
BR (1) BR112021006153A2 (enExample)
EA (1) EA202190954A1 (enExample)
IL (1) IL281979B2 (enExample)
MX (1) MX2021003867A (enExample)
SG (1) SG11202102765RA (enExample)
WO (1) WO2020070225A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
CN115698060A (zh) 2020-03-10 2023-02-03 生命爱科 环肽
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
WO2024133925A1 (en) 2022-12-22 2024-06-27 Bioarctic Ab Antibody which binds to abetape3
WO2025262228A1 (en) 2024-06-20 2025-12-26 Bioarctic Ab Bispecific binding molecule

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013167681A1 (en) * 2012-05-10 2013-11-14 Georg-August-Universität Göttingen CONFORMATIONAL-SPECIFIC ANTIBODIES AGAINST Αβ OLIGOMERS

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US474900A (en) 1892-05-17 William byrnes
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
HUE033325T2 (en) * 2007-01-05 2017-11-28 Univ Zuerich Anti-beta-amyloid binder antibodies and their use
CN101883792B (zh) 2007-10-29 2014-08-27 基因创新有限公司 特异于β-淀粉状蛋白肽的新抗体以及其用作诊断剂或药物的用途
US8795664B2 (en) 2010-06-04 2014-08-05 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Monoclonal antibodies targeting amyloid beta oligomers
WO2015173133A1 (en) 2014-05-12 2015-11-19 Chiesi Farmaceutici S.P.A. Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy
NZ739181A (en) * 2015-07-16 2023-05-26 Vivoryon Therapeutics N V Anti-pyroglutamated amyloid beta humanized antibodies
CN111518206B (zh) * 2019-02-01 2022-03-29 长春金赛药业有限责任公司 人源化抗Aβ单克隆抗体及其应用
CN115698060A (zh) * 2020-03-10 2023-02-03 生命爱科 环肽

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013167681A1 (en) * 2012-05-10 2013-11-14 Georg-August-Universität Göttingen CONFORMATIONAL-SPECIFIC ANTIBODIES AGAINST Αβ OLIGOMERS

Also Published As

Publication number Publication date
CN113056480B (zh) 2025-06-13
CA3114669A1 (en) 2020-04-09
KR102862077B1 (ko) 2025-09-18
WO2020070225A1 (en) 2020-04-09
EA202190954A1 (ru) 2021-06-29
AU2019354714B2 (en) 2026-05-21
JP2022513331A (ja) 2022-02-07
MX2021003867A (es) 2021-09-08
AU2019354714A1 (en) 2021-04-29
CN113056480A (zh) 2021-06-29
IL281979B1 (en) 2025-05-01
IL281979B2 (en) 2025-09-01
US20230203140A9 (en) 2023-06-29
US12297261B2 (en) 2025-05-13
KR20210080400A (ko) 2021-06-30
EP3861023A1 (en) 2021-08-11
SG11202102765RA (en) 2021-04-29
JP7610515B2 (ja) 2025-01-08
IL281979A (en) 2021-05-31
US20210347867A1 (en) 2021-11-11
BR112021006153A2 (pt) 2021-06-29

Legal Events

Date Code Title Description
SREP Specification republished